Novartis   4Q Revenues: $14.8 billion (flat) 4Q Earnings: $2.1 billion (+72%) YTD Revenues: $56.7 billion (-3%) YTD Earnings: $9.6 billion (+4%) Comments: Pharmaceutical sales were flat at $8.3 billion in the quarter. Products launched since 2007 generated $3.1 billion or 38% of sales, up 26%, offsetting the loss of exclusivity for Diovan HCT in the U.S. Alcon sales were up 6% to $2.6 billion, with the Surgical franchise up 8%, Ophthalmic Pharmaceuticals up 5%, and Vision Care up 4%. Sandoz ...